A major clinical trial has revealed that daraxonrasib, a new targeted oral therapy, could significantly improve outcomes for patients with advanced pancreatic cancer.
The study of 500 patients with metastatic disease found that those treated with daraxonrasib survived an average of 13.2 months, compared with about 6.6–6.7 months for patients receiving standard chemotherapy.
Daraxonrasib works by targeting KRAS mutations, which drive cancer growth in more than 90% of pancreatic ductal adenocarcinoma cases. Researchers also reported fewer side effects than chemotherapy. While regulatory approval is still required, the results offer new hope for patients facing one of the deadliest forms of cancer. – The Guardian (5 June 2026)